邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

全面评估，合理决策：基于胰高血糖素样肽1受体激动剂用药风险的最新发现

何丽云,  张化冰,  李玉秀

downloadPDF
文章导航 > 协和医学杂志  > 2022 >  13(6): 948-952
何丽云, 张化冰, 李玉秀. 全面评估，合理决策：基于胰高血糖素样肽1受体激动剂用药风险的最新发现[J]. 协和医学杂志, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391
引用本文: 何丽云, 张化冰, 李玉秀. 全面评估，合理决策：基于胰高血糖素样肽1受体激动剂用药风险的最新发现[J]. 协和医学杂志, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391
shu
HE Liyun, ZHANG Huabing, LI Yuxiu. Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391
Citation: HE Liyun, ZHANG Huabing, LI Yuxiu. Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391
shu

全面评估，合理决策：基于胰高血糖素样肽1受体激动剂用药风险的最新发现

doi: 10.12290/xhyxzz.2022-0391

  • 中国医学科学院北京协和医院内分泌科 国家卫生健康委员会内分泌重点实验室，北京 100730

基金项目: 

北京市自然科学基金 M22014

中国医学科学院医学与健康科技创新工程项目 2021-1-I2M-002

详细信息
    通讯作者:

    张化冰, E-mail: huabingzhangchn@163.com

  • 中图分类号: R589;R452

Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists

  • Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

Beijing Natural Science Foundation M22014

CAMS Innovation Fund for Medical Sciences 2021-1-I2M-002

More Information

    摘要
  • 摘要: 胰高血糖素样肽1受体激动剂(glucagon-like peptide-1 receptor agonists, GLP-1RAs)作为一种新型降糖药物，被广泛应用于2型糖尿病的治疗。GLP-1RAs能够有效降低血糖且低血糖风险小，此外，GLP-1RAs减重效果显著，兼具一定的心血管及肾脏保护作用; 轻中度胃肠道症状是GLP-1RAs最常见的不良反应，一般随时间延长可逐渐减轻。最新研究显示，GLP-1RAs的使用与胆囊或胆道疾病发生风险相关，尤其在高剂量、长时间使用以及用于减重治疗时，风险显著增加，但胆囊或胆道疾病的绝对风险不高。临床医生需全面权衡GLP-1RAs使用的获益与风险，并与患者共同作出合理决策。
    Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), as a kind of novel hypoglycemic agent, are widely used in patients with type 2 diabetes. GLP-1RAs are effective in glycemic control with low risk of hypoglycemia, significant weight loss, and cardiovascular benefit and renal protection. The most common adverse effects of GLP-1RAs are mild to moderate gastrointestinal symptoms, which generally resolve over time. The use of GLP-1RAs also increases the risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss, but the absolute risk of gallbladder or biliary tract disease is small. Clinicians and patients need to carefully weigh the benefits and risks of GLP-1RAs to make decisions for the rational use of GLP-1RAs.
    作者贡献：何丽云、张化冰负责查阅文献、撰写论文; 张化冰、李玉秀负责论文构思及终稿审核、修订。
    利益冲突：所有作者均声明不存在利益冲突
    • HTML全文
    • 参考文献(38)
  • [1] Alicic RZ, Cox EJ, Neumiller JJ, et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence[J]. Nat Rev Nephrol, 2021, 17: 227-244. doi:  10.1038/s41581-020-00367-2
    [2] Kalyani RR. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes[J]. N Engl J Med, 2021, 384: 1248-1260. doi:  10.1056/NEJMcp2000280
    [3] Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes[J]. Lancet Diabetes Endocrinol, 2021, 9: 525-544. doi:  10.1016/S2213-8587(21)00113-3
    [4] Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care[J]. Lancet Diabetes Endocrinol, 2021, 9: 46-52. doi:  10.1016/S2213-8587(20)30343-0
    [5] Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison[J]. J Am Coll Cardiol, 2022, 79: 1849-1857.
    [6] Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art[J]. Mol Metab, 2021, 46: 101102. doi:  10.1016/j.molmet.2020.101102
    [7] Ceriello A, Prattichizzo F, Phillip M, et al. Glycaemic management in diabetes: old and new approaches[J]. Lancet Diabetes Endocrinol, 2022, 10: 75-84. doi:  10.1016/S2213-8587(21)00245-X
    [8] Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials[J]. BMJ, 2021, 372: m4573.
    [9] Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications[J]. Lancet, 2021, 398: 262-276. doi:  10.1016/S0140-6736(21)00536-5
    [10] Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol, 2021, 9: 653-662. doi:  10.1016/S2213-8587(21)00203-5
    [11] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13: 315-409. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK202108007.htm
    [12] Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline[J]. BMJ, 2021, 373: n1091.
    [13] Marx N, Grant PJ, Cosentino F. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk[J]. Eur Heart J, 2020, 41: 329-330. doi:  10.1093/eurheartj/ehz853
    [14] He L, Yang N, Xu L, et al. Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis[J]. Diabetes Ther, 2020, 11: 2121-2143. doi:  10.1007/s13300-020-00882-2
    [15] Lee MMY, Ghouri N, McGuire DK, et al. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes[J]. Diabetes Care, 2021, 44: 1236-1241. doi:  10.2337/dc20-3007
    [16] Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial[J]. JAMA, 2015, 314: 687-699. doi:  10.1001/jama.2015.9676
    [17] Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management[J]. N Engl J Med, 2015, 373: 11-22. doi:  10.1056/NEJMoa1411892
    [18] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity[J]. N Engl J Med, 2021, 384: 989-1002. doi:  10.1056/NEJMoa2032183
    [19] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: the STEP 4 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1414-1425. doi:  10.1001/jama.2021.3224
    [20] Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: the STEP 3 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1403-1413. doi:  10.1001/jama.2021.1831
    [21] Christensen RM, Juhl CR, Torekov SS. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists[J]. Drug Saf, 2019, 42: 957-971. doi:  10.1007/s40264-019-00812-7
    [22] US Food, Drugs Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014[EB/OL]. (2021-06-04)[2022-07-01]. https://www.fda.gov/news-events/press-announcements/fda-appro- ves-new-drug-treatment-chronic-weight-management-first-2014.
    [23] Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials[J]. Diabetes Obes Metab, 2017, 19: 336-347. doi:  10.1111/dom.12824
    [24] Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study[J]. JAMA Intern Med, 2013, 173: 534-539. doi:  10.1001/jamainternmed.2013.2720
    [25] Douros A, Filion KB, Yin H, et al. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy[J]. Diabetes Care, 2018, 41: 2330-2338. doi:  10.2337/dc17-2280
    [26] Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106: 912-921. doi:  10.1210/clinem/dgaa891
    [27] Pizzimenti V, Giandalia A, Cucinotta D, et al., Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database[J]. J Clin Pharm Ther, 2016, 41: 116-118. doi:  10.1111/jcpt.12373
    [28] Faillie JL, Yu OH, Yin H, et al. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus[J]. JAMA Intern Med, 2016, 176: 1474-1481. doi:  10.1001/jamainternmed.2016.1531
    [29] Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined[J]. N Engl J Med, 2021, 384: 1719-1730. doi:  10.1056/NEJMoa2028198
    [30] le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial[J]. Lancet, 2017, 389: 1399-1409. doi:  10.1016/S0140-6736(17)30069-7
    [31] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl J Med, 2016, 375: 1834-1844. doi:  10.1056/NEJMoa1607141
    [32] Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial[J]. Diabetes Care, 2019, 42: 1912-1920. doi:  10.2337/dc19-0415
    [33] He L, Zhang H. Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2021, 385: 2106-2107.
    [34] He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials[J]. JAMA Intern Med, 2022, 182: 513-519. doi:  10.1001/jamainternmed.2022.0338
    [35] Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study[J]. BMJ, 2018, 363: k4880.
    [36] Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss[J]. Am J Surg, 1995, 169: 91-96; discussion 96-97. doi:  10.1016/S0002-9610(99)80115-9
    [37] Shiffman ML, Kaplan GD, Brinkman-Kaplan V, et al. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program[J]. Ann Intern Med, 1995, 122: 899-905. doi:  10.7326/0003-4819-122-12-199506150-00002
    [38] He L, Wang J, Ping F, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials[J]. BMJ, 2022, 377: e068882.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  165
  • HTML全文浏览量:  88
  • PDF下载量:  30
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-07-14
  • 录用日期:  2022-08-29
  • 网络出版日期:  2022-09-27
  • 刊出日期:  2022-11-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！